Comparative Pharmacology
Head-to-head clinical analysis: EZALLOR SPRINKLE versus ZEGERID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EZALLOR SPRINKLE versus ZEGERID.
EZALLOR SPRINKLE vs ZEGERID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
20 mg or 40 mg orally once daily before a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
1.0–1.5 hours in plasma; however, the pharmacodynamic half-life is longer due to irreversible inhibition of H+/K+-ATPase; drug effect persists for 24 hours after single dose.
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Approximately 82% renal (as metabolites), 18% fecal (via bile); less than 1% unchanged in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor